Nanjing Vazyme Biotech Co., Ltd.

Nanjing Vazyme Biotech Co., Ltd. saw its stock price decline significantly today, contrasting with broader market trends. Despite a recent weekly gain, the company faces ongoing challenges, including a substantial annual drop in net sales and operating profit, raising concerns about its long-term growth potential and operational efficiency.

Nanjing Vazyme Biotech Co., Ltd. faced a notable stock decline today, reflecting ongoing challenges. The company has experienced a significant drop in net sales and operating profit over recent years, alongside a concerning Return on Capital Employed. Its performance continues to lag behind the broader market index.

Nanjing Vazyme Biotech Co. saw a notable stock price increase on June 29, 2026, outperforming the China Shanghai Composite. Despite recent gains, the company has faced long-term challenges, including declining net sales and low profitability, with a market capitalization of CNY 6,794 million.

Nanjing Vazyme Biotech Co., Ltd. saw a notable rise in its stock today, reaching an intraday high amid ongoing challenges in the Pharmaceuticals & Biotechnology sector. Despite recent gains, the company has struggled with long-term growth, facing declining net sales and negative returns on equity.

Nanjing Vazyme Biotech Co., Ltd. saw a notable stock price increase on June 18, 2026, amid a declining broader market. The company has shown strong weekly performance but a slight monthly decline. Year-to-date, it lags behind the Shanghai Composite, with a year-long decline contrasting the index's gains.

Nanjing Vazyme Biotech Co., Ltd. faced a notable stock decline, contrasting with broader market trends. The company has experienced significant cumulative losses over various timeframes, alongside challenges such as low profitability and declining net sales. Its market capitalization stands at CNY 8,265 million amid ongoing financial difficulties.